Roivant Sciences Ltd. (NASDAQ: ROIV) was upgraded by analysts at Cantor Fitzgerald to a "strong-buy" rating.
Roivant Sciences Ltd. (ROIV)
Company Research
Source: MarketBeat
Impact Snapshot
Event Time:
ROIV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ROIV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ROIV alerts
High impacting Roivant Sciences Ltd. news events
Weekly update
A roundup of the hottest topics
ROIV
News
- Roivant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) StudiesGlobeNewswire
- Roivant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) ProgramsGlobeNewswire
- Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna [Yahoo! Finance]Yahoo! Finance
- Early Warning Report Issued Pursuant to National Instrument 62-103: Roivant announces Resignation and Replacement of Arbutus BoardGlobeNewswire
- Will Moderna Stock Drop to $25? 1 Wall Street Analyst Thinks So. [Yahoo! Finance]Yahoo! Finance
ROIV
Earnings
- 2/10/25 - Beat
ROIV
Sec Filings
- 3/24/25 - Form 4
- 3/24/25 - Form 4
- 3/24/25 - Form 4
- ROIV's page on the SEC website